SEC EDGARAUG 311 min read$DGX

PREVOZNIK MICHAEL E sold $5.5M of DGX

PREVOZNIK MICHAEL E (SVP & General Counsel) sold 22,677 shares of QUEST DIAGNOSTICS INC (DGX) at an average of $243.11 ($242.88–$244.51, $5.51M total) across 3 trades on 2026-08-28 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · PREVOZNIK MICHAEL E

Published Aug 31, 2026, 8:37 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Aug 31, 2026, 9:34 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$DGX

Bearish

medium confidence

Mentioned

$DGX

Relevance

5/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$DGXBearishMed

Why it matters

The disclosed sale provides fresh data on insider sentiment and may influence short‑term price action.

Market read

First‑report insider sale of $5.5 M; relevant for traders monitoring DGX.

What to watch

Potential upcoming earnings release could offset the negative sentiment from the insider sale.

Relevance 5/10Novelty 7/10Timing: post‑market 2026‑08‑28

Background

SEC Form 4 filing discloses insider transaction for Quest Diagnostics (DGX).

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$DGXBearishMedium confidence

Context

SVP & General Counsel sold 22,677 shares for $5.5M via a 10b5‑1 plan

Expected impact

Possible short‑term dip as market digests the $5.5M sale.

Evidence & confidence

A senior officer off‑loading a sizable stake signals reduced confidence; however, the sale is pre‑arranged under a 10b5‑1 plan, limiting immediate informational value.

Market effects

Sector

Minimal impact on healthcare diagnostics sector; insider activity is company‑specific.

Regional

U.S. market only; no broader regional effect.

Global

Low global relevance.

Counterpoint

What could challenge this read

The sale may be purely portfolio rebalancing under a 10b5‑1 plan, not a bearish signal.

Key entities

Company
Quest Diagnostics Inc.
Issuer of the Form 4 filing.
Individual
Michael E. Prevoznick
SVP & General Counsel, insider seller.

Read at source ← All news

SEP 16

$RDNTHighAI 8/10

Testing & Diagnostics Services Stocks Q2 Results: Benchmarking Guardant Health (NASDAQ:GH)

Guardant Health, RadNet (NASDAQ:RDNT), Labcorp (NYSE:LH), NeoGenomics (NASDAQ:NEO), and Quest (NYSE:DGX) reported Q2 results. RadNet saw 25% revenue growth, beating estimates. Labcorp's revenue grew 5.8%, meeting expectations but underperforming peers. NeoGenomics and Quest both beat estimates with 11.2% and 10.2% revenue growth, respectively. Stocks have risen since reporting.

yahoo.com3 min

AUG 28

$LLYHighAI 9/10

FDA Clears New Alzheimer’s Blood Test for People 55 and Older - WOWO News/Talk 92.3 FM and 1190 AM

The FDA cleared a new blood test, Elecsys pTau217, developed by Roche and Eli Lilly, for evaluating Alzheimer's disease in people 55+. The test measures phosphorylated tau 217, a biomarker linked to amyloid pathology. It is designed to support diagnostic assessments but not replace full medical evaluations. Roche and Lilly aim to make the test accessible in primary care settings, potentially improving early diagnosis and treatment planning.

wowo.com2 min

AUG 24

$DGXMedAI 8/10

Quest Diagnostics to Offer FDA-Cleared Roche pTau217 Blood Test to Assess Alzheimer's Disease Pathology

Quest Diagnostics (DGX) will offer Roche's FDA-cleared pTau217 blood test for Alzheimer's assessment, expanding its AD-Detect® portfolio. The test will be available Q4 2026. Quest also launches a new multi-biomarker AD-Detect test with a 10% indeterminate rate, aiming to provide more actionable insights for patients.

prnewswire.com2 min

AUG 21

$DGXHighAI 8/10

Quest Diagnostics Incorporated (DGX) Hit a 52 Week High, Can the Run Continue?

Quest Diagnostics (DGX) hit a 52-week high, driven by consistent earnings beats. It reported EPS of $3.12 vs. $2.81 estimate, with revenue beating consensus by 2.15%. The company has a Zacks Rank of #2 (Buy) and a VGM Score of B. DGX trades at 21.6X current fiscal year EPS estimates. Option Care Health (OPCH), a peer, also shows strong fundamentals and a Zacks Rank of #2.

sharewise.com2 min

AUG 19

$MCKMedAI 8/10

Winners And Losers Of Q2: McKesson (NYSE:MCK) Vs The Rest Of The Healthcare Providers & Services Stocks

McKesson (MCK) fell 9.1% post-earnings despite a solid quarter. AdaptHealth (AHCO) missed revenue and EBITDA estimates, down 46.2%. Elevance Health (ELV) beat revenue and EPS estimates but lost customers, down 7.4%. Quest (DGX) topped expectations, up 12.6%.

finance.yahoo.com3 min

JUL 27